

Ref: SEC/SE/2025-26

Date: August 1, 2025



To,  
Corporate Relations Department  
**BSE Ltd.**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai- 400001

Listing Department  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block Bandra – Kurla Complex  
Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol: DABUR

**Sub: Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2025**

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose copies each of the Mint (English newspaper) and Deshbandhu (Hindi newspaper) dated August 1, 2025, in which Quick Response Code and the details of the webpage where complete financial results of the Company for the quarter ended June 30, 2025 are accessible to the Investors, have been published. The aforesaid results were approved by the Board of Directors in their meeting held on July 31, 2025.

Submitted for your kind information and records.

Thanking you,

Yours faithfully

For **Dabur India Limited**

  
(Ashok Kumar Jain)

Group Company Secretary and Chief Compliance Officer

Encl: as above



# Trump and Dimon are talking again after yearslong rift

America's most powerful banker and the president have met twice in the past two months

Alexander Saeedy & Annamaria Andriotis  
feedback@livemint.com

JPMorgan Chase Chief Executive Jamie Dimon visited the White House twice in the past two months, a sign of detente after years of tension between the head of America's biggest bank and President Trump.

Last week, Dimon met with Trump in the Oval Office to discuss the economy, trade and financial regulation, people familiar with the matter said. Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick were also in attendance, the people said.

At the meeting, Dimon congratulated Trump on his recent trade deal with Japan. They discussed the continuing shortage of affordable housing and the impact of post-2008 financial crisis regulations on American homeownership, the people said.

Their conversation also broached a topic they have publicly disagreed on: interest rates. Trump has continually bashed Federal Reserve chair Jerome Powell over the central bank's monetary policy and has threatened to remove him. Dimon has been steadfast in his support of Powell and the Fed's independence more broadly, adding that political attempts to force interest rates lower often have the opposite effect.

In last week's meeting, Dimon told the president that interest rates could come down if the economy is sufficiently strong, a person familiar with the matter said. That message echoes what Bessent told Trump as he tried to make his case for not firing Powell, *The Wall Street Journal* previously reported.

Later in the week, Trump toured a construction project at the Fed that has become a point of contention for the president's supporters against Powell. He said then he wasn't planning to



Last week, Dimon met with Trump in the Oval Office to discuss the economy, trade and financial regulation.

REUTERS

remove Powell, though Trump reiterated he would like rates lowered. On Wednesday, he again echoed calls for rates to go down, citing better-than-expected economic data.

The Fed on Wednesday stood pat again on interest rates, although two Trump-appointed governors dissented from the 12-person committee's decision.

In June, Dimon had another meeting with Trump and other officials including Vice President JD Vance, the people said.

Before the summer meetings, Dimon and Trump hadn't had a substantive conversation for years, the *Journal* reported. They had also lobbed rounds of public insults at each other over the years.

In the first administration, Dimon was among the CEOs who dissolved a

council of leaders after Trump's comments about racial tension in Charlottesville, Va. Dimon later compared Trump's challenge of the 2020 election results to treason.

In 2023, Trump called Dimon "highly overrated" after Dimon urged business leaders to back Nikki Haley in the Republican primary. He has also accused JPMorgan of discriminating against conservatives.

But there have been signs that Dimon and Trump were looking to turn the page.

Dimon has often said that as the chief executive of America's biggest bank, he wants to meet with leaders no matter their political ideology to help them improve the country. He declares himself a patriot who puts country above politics and his own bank.

THE WALL STREET JOURNAL

In January, Dimon had said that the world should listen to Trump's views and that he was making the right decisions on a number of matters. He has supported some of the new tariffs on foreign trading partners, especially those that help protect national security. He also has said that immigration at the Southern border needed to be addressed and has criticized Democrats for having "big hearts" and "little brains."

When Trump's April tariff announcements sent markets into turmoil, Dimon went on television, saying a trade war risked plunging the economy into a recession.

Trump later cited Dimon's comments on the risks as a factor he considered before deciding to pause most of them on April 9. Trump has also said he respects Dimon's view on the economy and the vast banking franchise he has built.

©2025 DOW JONES & COMPANY, INC.

# Mounjaro as good as older drug on heart-attack risk

Bloomberg  
feedback@livemint.com

A trial of Eli Lilly & Co.'s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity.

A head-to-head study of the two treatments—Lilly's largest and longest of Mounjaro to date—was designed to prove what's called non-inferiority, that Mounjaro was an acceptable alternative when it comes to reducing risks from major cardiovascular events compared with Trulicity.

While it achieved that target, the study dashed investors hopes that Mounjaro would be meaningfully better than its older drug. "There's no mention of superiority, which was also tested for by Lilly," said Bloomberg Intelligence analyst Michael Shah. "So it will likely be received negatively by the market."

Shares in the obesity-drug maker dropped as much as 5.3% in premarket trading in New York. Lilly's shares were down nearly 2% this year as of Wednesday's close, compared with an 8% rise in the S&P 500.

More than 13,000 people with type 2 diabetes and a history of heart disease were enrolled in Lilly's trial, during which they were treated with either Mounjaro or Trulicity and followed for an average of about four years. The results showed that Mounjaro was effective at reducing the risk of heart attacks and strokes and cardiovascular death, but not significantly better than the older drug, according to results shared by Lilly on

More than 13,000 people with type 2 diabetes and a history of heart disease were enrolled in Lilly's trial



The study dashed investors hopes that Mounjaro would be meaningfully better than its older drug.

REUTERS

Thursday. Mounjaro was tied to other positive health impacts. Patients on the drug were 16% less likely to die from any cause than those on Trulicity. Mounjaro patients also saw greater improvements in blood sugar levels, weight loss and blood pressure, Lilly said. The most commonly reported side effects were mild and gastrointestinal-related with both drugs.

The fact that patients lost more weight on Mounjaro but saw about the same reduction in risk from cardiovascular events suggests the class of medications—known as GLP-1s—may have protective effects on the heart that are independent of weight loss.

Lilly will present the study at a medical conference in September. Mounjaro is already approved as a treatment for type 2 diabetes, but Lilly plans to submit the new findings to global drug regulators by the end of the year in hopes of expanding its label to include cardiovascular risk reduction.

"These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes

and cardiovascular disease," Ken Custer, president of Lilly's cardiometabolic business, said in a statement. Trulicity has established heart benefits. Back in 2020, US regulators gave it an expanded label for risk reduction from major cardiovascular events in people with type 2 diabetes.

Lilly and rival Novo Nordisk A/S—the maker of Ozempic and Wegovy—have been racing to study their drugs in a range of conditions beyond obesity and diabetes. While most insurers cover the treatments for diabetes, many have been reluctant to cover them for weight loss.

Novo has already demonstrated that both Ozempic and Wegovy reduce the risk of heart attacks and strokes in patients with obesity and diabetes. Both drugs carry labels reflecting those benefits, giving Novo an advantage in coverage negotiations with insurers and government programs.

Lilly, however, has managed to take significant market share from Novo—even without a label for heart disease.

Lilly isn't running trials of its obesity drug Zepbound specifically for cardiovascular risk reduction. Instead, it's studying whether the drug can reduce the risk of death from all causes in a large, multiyear trial.

**NASHIK MUNICIPAL CORPORATION, NASHIK**  
**PUBLIC HEALTH ENGINEERING DEPARTMENT**  
**(WATER SUPPLY)**  
**Tender Notice No. 08/2025-26**

Nashik Municipal Corporation, Nashik invites bids Augmentation of Mukane Water Supply Scheme, WTP, Construction of Gravity Main from Vilholi to Gandhi nagar, Sadhugram & Nilgiri Baug WTP for Sinhaastha Kumbh This Work publish Tender Notice No. 08/2025-26 Last Date & Time of Issue of Blank Tender form 30/07/2025 to 20/08/2025 UPTO 3.00 website <http://mahatenders.gov.in> Last Date of receipt of Sealed Tender form 20/08/2025 Public Health Engineering Department, (WS) Nashik Municipal Corporation, Nashik. The detailed tender notice, document would be available on [www.mahatenders.gov.in](http://www.mahatenders.gov.in)

**Note:** All the following necessary instructions / clarifications will be published on the online website.

**Sd/-** Superintending Engineer, (WS) Public Health Engineering Department (WS) Nashik Municipal Corporation, Nashik

**Sd/-** Commissioner and Administrator Nashik Municipal Corporation, Nashik

जमसंपर्क/जा.क्र./१८७/२०२५ दि.३०/०७/२०२५ सर्व नामिकांनी पाणी काटकसरने वापरावे.

**pnb MetLife**  
*Mitkar life aage badhaein*

**PNB MetLife India Insurance Company Limited: Newspaper Publication**  
Registration Number: 117 dated August 6, 2001 with IRDAI  
(Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations)

(₹ in Lakhs)

Sr. No.	Particulars	Quarter ending June 30, 2025	Year ending March 31, 2025	Quarter ending June 30, 2024
1	Premium Income (Gross) (Refer note (c))	2,24,330	1,75,239	2,04,407
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	12,095	32,535	5,036
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items) (Refer note (e))	12,095	32,535	5,036
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	11,968	32,535	4,747
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	NA	NA	NA
6	Equity Share Capital (as at date)	2,04,947	2,01,288	2,01,288
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet (Refer note (f))	42,458	4,149	-
8	Earning per share (Face value of ₹10 each) a. Basic (Not annualized for three months) (in ₹) b. Diluted (Not annualized for three months) (in ₹)	0.59 0.59	1.62 1.62	0.24 0.24
9	Debt-equity ratio (no. of times)	0.16	0.19	0.23
10	Debt service coverage ratio (no. of times)	15.94	11.04	7.22
11	Interest service coverage ratio (no. of times)	15.94	11.04	7.22

**Footnotes**

a) This format is modified to reflect the terminology used in the Insurance Act IRDAI Regulations.  
b) The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the Stock Exchange and the Company's website 'https://www.pnbmetlife.com'.  
c) Premium income is gross of reinsurance and net of GST.  
d) Line Item No. 5 would be disclosed when Ind AS become applicable to Insurance companies.  
e) Net Profit / (Loss) before tax, for the period is Profit / (Loss) before tax as appearing in Profit and Loss Account (Shareholders' account).  
f) Reserves are excluding Revaluation reserve and fair value change account.  
g) The Company has issued and allotted 4,000 unsecured, subordinated, listed, rated, redeemable, taxable, non-convertible debentures (NCDs) in the nature of 'Subordinated Debt' in accordance with IRDAI (Other Forms of Capital) Regulations, 2015 of face value of ₹ 1,000 thousands (each at par) aggregating to ₹ 4,000,000 thousands through private placement on January 27, 2022.  
h) During the period, the Company completed right issue of equity shares. A total of 3,65,85,363 fully paid equity shares were allotted to existing shareholders at a price of ₹ 82 per share (comprising a, face value of ₹10/- each and premium of ₹72/- per share).  
i) Debt-equity ratio is calculated as Total borrowings divided by Net Worth  
Net Worth = Share Capital + Free Reserves and Surplus + Credit / (Debit) Fair Value Change Account - Debit Balance in Profit and Loss.  
j) Debt service coverage ratio is calculated as Profit before interest and tax divided by interest expense together with principal repayments of long term debt during the period.  
k) Interest service coverage ratio is calculated as Profit before interest and tax divided by interest expense.  
l) \*-Exceptional and / or Extraordinary items adjusted in the Statement of Policyholders' and Shareholders' account in accordance with Ind - AS Rules / AS Rules, whichever is applicable.

PNB MetLife India Insurance Company Limited, Registered office: Unit No. 701, 702 & 703, 7th Floor, West Wing, Raheja Towers, 26/27 M G Road, Bangalore -560001, Karnataka. IRDA of India Registration number 117 dated August 6, 2001 with IRDAI (Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations) CI No. U66010KA2001PLC028883. The marks "PNB" and "MetLife" are registered trademarks of Punjab National Bank and Metropolitan Life Insurance Company, respectively. PNB MetLife India Insurance Company Limited is a licensed user of these marks. Call us Toll-free at 1-800-425-6969, Website: [www.pnbmetlife.com](http://www.pnbmetlife.com) Email: [indiaservice@pnbmetlife.co.in](mailto:indiaservice@pnbmetlife.co.in) or write to us at 1st Floor, Techniplex-1, Techniplex Complex, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062. AD-NF/2025-26/040.

For and on behalf of the Board of Directors

**Mohit Burman**  
Chairman  
DIN: 00021963

Place: New Delhi  
Date: July 31, 2025

**Sameer Bansal**  
Managing Director and CEO  
DIN No. 10642045  
Place: Mumbai  
Date: July 31, 2025

**DABUR INDIA LIMITED**  
Regd. Office: 8/3, Asaf Ali Road, New Delhi - 110 002  
CIN - L24230DL1975PLC007908  
Tel. No.: 011-23253488, Fax No.: 011-23222051  
Website: [www.dabur.com](http://www.dabur.com) | E-mail: [corpcomm@dabur.com](mailto:corpcomm@dabur.com)

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025**

The consolidated and standalone unaudited financial results of the Company for the quarter ended June 30, 2025, approved by the Board of Directors in their meeting held on July 31, 2025, along with the Auditors' Limited Review Reports thereon (expressing an unmodified opinion), as filed with the Stock Exchanges under Regulations 33 and 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 are available on the Stock Exchanges websites ([www.bseindia.com](http://www.bseindia.com) & [www.nseindia.com](http://www.nseindia.com)), the Company's webpage ([www.dabur.com/investor/financial-information/results](http://www.dabur.com/investor/financial-information/results)) and can also be accessed by scanning the following Quick Response Code.

For and on behalf of the Board of Directors

Place: New Delhi  
Date: July 31, 2025

**Mohit Burman**  
Chairman  
DIN: 00021963

**SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES**

As mandated by SEBI a 'Special Window' has been allowed from July 07, 2025 to January 06, 2026 to facilitate re-lodgement of physical share transfer requests that were originally lodged before April 01, 2019 but were rejected/ returned due to deficiencies. Investors who missed the earlier cut-off of March 31, 2021, are encouraged to utilize this special window and submit the requisite documents to the Company/ Company's RTA - KFin Technologies Limited.

